The clinical failure-strewn world of Alzheimer's disease (AD) awaits top-line, part A results due in April from Vtv Therapeutics Inc.'s phase III study called Steadfast with azeliragon, an antagonist of the receptor for advanced glycation end products (RAGE), and many hope the new approach can break through the development wall that other drug candidates have splattered themselves against. Read More
The biopharmaceutical sector got slammed in early February by an unexpected market correction when the Dow plummeted 1,175 points in a single day, the largest single points drop on record. The market did, however, get off the mat and recover some of its losses as the month rolled on, but it remained susceptible to any negative economic or financial news and often tumbled hundreds of points in a single day following such announcements. Read More
